Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-05-13

Clinical Trial Update: Blinatumomab Bridging Therapy for BALL [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating blinatumomab as bridging therapy for B-cell acute lymphoblastic leukemia was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BLINCYTO (BLINATUMOMAB)

Snippet

Sponsor: Michael Burke | Conditions: B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2025-05-13